Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of nab-paclitaxel in recurrent platinum-resistant ovarian cancer
ChiCTR1900022877Phase 2Not yet recruiting
- Sponsor
- Changzhi People's Hospital
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in ovarian cancer, sponsored by Changzhi People's Hospital. Primary endpoints: Progression-free survival and Safety. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on ChiCTR1900022877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022877.